Collectively, our results confirmed the feasibility and reliability of the predictive mode based on HYP.SIG for assessing response to anti-PD-L1/PD1 or anti-CTLA-4 immunotherapy at the pan-cancer level. This evidence concerns the gene CTLA4 and cancer.